Drug-drug interactions (DDI) and genomic variation (PG) can lead to dangerously high
blood and tissue concentrations with some drugs but may be negligible with other drugs …

Abstract Background and Objective The magnitude of drug–drug interactions mediated by
cytochrome P450 (CYP) may depend on the genotype of polymorphic cytochromes. The …

FDA recommendations to manage polymorphic CYP‐mediated drug‐drug interactions
(DDIs) and gene‐drug interactions (GDIs) are typically similar. However, DDIs may not …

Currently, most guidelines on drug–drug interaction (DDI) neither consider the potential
effect of genetic polymorphism in the strength of the interaction nor do they account for the …

We investigated whether CYP2D6 extensive metabolizers carrying a nonfunctional allele
are at higher risk of phenoconversion to poor metabolizers in the presence of CYP2D6 …

Abstract Background and Objective Cytochrome P450 (CYP) 2C9 is the most common
CYP2C enzyme and makes up approximately onethird of total CYP protein content in the …

Interindividual variability in drug response depends on a number of genetic and
environmental factors. The metabolic enzymes are well known for their contribution to this …

We present a unified quantitative approach to predict the in vivo alteration in drug exposure
caused by either cytochrome P450 (CYP) gene polymorphisms or CYP-mediated drug–drug …

Human cytochrome P450 (CYP) is a superfamily of hemoproteins which oxidize a number of
endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four …

Background and objectives A genetic algorithm (GA) approach was developed to predict
drug-drug interactions (DDIs) caused by cytochrome P450 2C8 (CYP2C8) inhibition or …